Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Lexapro (escitalopram) is an SSRI that was developed by Lundbeck; it initially gained marketing approval for MDD in 2002 in the US. Lexapro is the S-enantiomer of citalopram, an SSRI that was also developed by Lundbeck, which first became available in 1989. Lexapro acts by binding with high affinity to serotonin (5-HT), thereby inhibiting serotonin reuptake; this results in the higher levels of serotonin that are believed to exert antidepressant effects.
Read Complete Report with TOC: http://www.radiantinsights.com/research/lexapro-major-depressive-disorder-forecast-and-market-analysis-to-2023
Scope
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lexapro including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lexapro for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Request Free Sample Of This Study @ http://www.radiantinsights.com/research/lexapro-major-depressive-disorder-forecast-and-market-analysis-to-2023#tabs-4
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lexapro performance
- Obtain sales forecast for Lexapro from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia).
Read Complete Report with TOC: http://www.radiantinsights.com/research/lexapro-major-depressive-disorder-forecast-and-market-analysis-to-2023
Scope
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lexapro including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lexapro for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Request Free Sample Of This Study @ http://www.radiantinsights.com/research/lexapro-major-depressive-disorder-forecast-and-market-analysis-to-2023#tabs-4
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lexapro performance
- Obtain sales forecast for Lexapro from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia).
No comments:
Post a Comment